Approximately 40% of all CRC tumors harbor an active mutation in the KRAS gene, leading to constitutive ERK/MAPK activation and loss of responsiveness to Cetuximab [7], whereas TRAIL sensitivity may be increased [25]. The gene discussed is KRAS; the disease is colorectal carcinoma.